ACTIVE IMMUNOTHERAPY Oncolytic Virus Therapy Using HSV-1
ACTIVE IMMUNOTHERAPY Oncolytic Virus Therapy Using HSV-1
复制标题
DOI：
10.1007/978-1-4614-3146-6_14
复制
发表时间：
2012-01-01
期刊：
影响因子：
--
通讯作者：
Todo, Tomoki
中科院分区：
文献类型：
--
作者：
Todo, Tomoki
单纯疱疹病毒1型（HSV-1）是一种具有良好治疗胶质瘤前景的病毒。它们可以原位复制、扩散并通过直接杀细胞作用表现出溶瘤活性。此外，在溶瘤活性过程中有效诱导特异性抗肿瘤免疫。G47 Delta是一种基因工程HSV-1，具有三重突变，实现了增强病毒在肿瘤细胞中的复制，强烈诱导抗肿瘤免疫，并增强了在正常组织中的安全性。G47 Delta在复发性胶质母细胞瘤患者中的临床试验已于2009年开始。HSV-1的优势之一是其在病毒基因组内掺入大的和/或多个转基因的能力。在临床前研究中，用编码免疫调节分子（如白介素12）的转基因"武装"溶瘤HSV-1已显示出极大地增强溶瘤HSV-1疗法的功效。使用HSV-1的溶瘤病毒疗法可能是一种有用的神经胶质瘤治疗方法，也可以作为有效的原位肿瘤疫苗接种。
Conditionally replicating herpes simplex viruses Type 1 (HSV-1) are promising therapeutic agents for glioma. They can replicate in situ, spread and exhibit oncolytic activity via a direct cytocidal effect. In addition, specific antitumor immunity is effectively induced in the course of oncolytic activities. G47 Delta is a genetically engineered HSV-1 with triple mutations that realized augmented viral replication in tumor cells, strong induction of antitumor immunity and enhanced safety in normal tissues. A clinical trial of G47 Delta in patients with recurrent glioblastoma has started in 2009. One of the advantages of HSV-1 is its capacity to incorporate large and/or multiple transgenes within the viral genome. In preclinical studies, "arming" of an oncolytic HSV-1 with transgenes encoding immunomodulatory molecules, such as interleukin 12, has been shown to greatly augment the efficacy of oncolytic HSV-1 therapy. Oncolytic virus therapy using HSV-1 may be a useful treatment for glioma that can also function as an efficient in situ tumor vaccination.